Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Therapeutics, Targets, and Chemical Biology

Delivery of Therapeutics Targeting the mRNA-Binding Protein HuR Using 3DNA Nanocarriers Suppresses Ovarian Tumor Growth

Yu-Hung Huang, Weidan Peng, Narumi Furuuchi, Jacquelyn Gerhart, Kelly Rhodes, Neelanjan Mukherjee, Masaya Jimbo, Gregory E. Gonye, Jonathan R. Brody, Robert C. Getts and Janet A. Sawicki
Yu-Hung Huang
Lankenau Institute for Medical Research, Wynnewood, Pennsylvania.Department of Biochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, Pennsylvania.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Weidan Peng
Lankenau Institute for Medical Research, Wynnewood, Pennsylvania.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Narumi Furuuchi
Lankenau Institute for Medical Research, Wynnewood, Pennsylvania.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacquelyn Gerhart
Genisphere, LLC, Hatfield, Pennsylvania.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kelly Rhodes
Genisphere, LLC, Hatfield, Pennsylvania.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Neelanjan Mukherjee
Berlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine, Berlin, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masaya Jimbo
Department of Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gregory E. Gonye
NanoString Technologies, Seattle, Washington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan R. Brody
Department of Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert C. Getts
Genisphere, LLC, Hatfield, Pennsylvania.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Janet A. Sawicki
Department of Biochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, Pennsylvania.Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: sawickij@mlhs.org
DOI: 10.1158/0008-5472.CAN-15-2073
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Additional Files

  • Supplementary Data

    • Supplementary Figure S1 - Supplementary Fig. S1. Location of HuR (human) inhibitory oligonucleotides.
    • Supplementary Figure S2 - Supplementary Fig. S2. A. HuR mRNA levels measured by RT-PCR in A2780 transiently-transfected with siHuR and siCtrl. B. Constitutively expressed shHuR maintains inhibition of HuR expression in ovarian tumor cells. Western blots of total cell lysates of parental and shHuR-constitutively expressing A2780, OVCAR5, and OVCA420 cells at various passage numbers. C. HuR mRNA levels measured by RT-PCR in late passages of A2780 and OVCAR5 cells expressing shHuRc or shCtrl. * = p<0.0005
    • Supplementary Figure S3 - Supplementary Fig. S3. A. HuR mRNA levels in parental and transfected OVCAR3 cells upon shHuR induction with 1mg/ml DOX. PAR = parental. B. Western blots of cell lysates following incubation with various concentrations of doxycycline. C. OVCAR3 toxicity following incubation with various concentrations of doxycycline.
    • Supplementary Figure S4 - Supplementary Fig. S4. TUNEL and Ki67 staining for detection of proliferating and apoptotic cells, respectively. A. TUNEL and Ki67 stained sections of four OVCAR5-shHuR and four OVCAR5-shCtrl ovarian xenografts. Areas of Ki67- cells are delineated with a white dotted line. B. In vitro staining of parental OVCAR5 cells, OVCAR5-shCtrl cells and OVCAR5-shHuR cells. Ki67+ cells and DAPI-stained cells were counted in three 1.4mm2 fields to determine % Ki67+ cells. * indicates p = 0.003 between parental and shHuR cells. DAPI stains nuclei in panels A and B. White bar = 50 mm.
    • Supplementary Figure S5 - Supplementary Fig. S5. A. 3DNA<sup>®</sup> dendrimer platform for in vivo tumor-targeted delivery of siHuR. B. Ovarian cancer cell lines, non-tumorigenic human immortalized ovarian epithelial cells (HIO 80 and HIO 120), and murine ID8-Fluc cells express the folate receptor. C. Serum stability. siHuR incubated for 1 hr at 37<sup>o</sup>C, then assayed on a 10%Tris/Borate/Urea PAGE. Sense strand: 42 bases (modified bases + extension); Antisense strand: 22 bases (modified bases). D. In vitro siHuR knockdown activity. siHuR (13nM) was combined with lipofectamine or targeted 3DNA dendrimer and incubated with A2780 cells overnight in 10% serum-containing medium. Dendrimer plus a scrambled siHuR had no knockdown activity (not shown).
    • Supplementary Figure S6 - Supplementary Fig. S6. Biodistribution of Cy3-conjugated 3DNA +/- conjugation to folic acid (FA). Following systemic delivery of FA-targeted Cy3-3DNA to ovarian tumor bearing mice, significant Cy3 fluorescence was observed in ovarian tumors, lesser amount in normal ovaries of tumor-bearing mice, very low amounts in brain, liver, spleen, and lung (white arrows), and no fluorescence was observed in heart. No fluorescence was observed in the ovary of non-tumor bearing mouse.
    • Supplementary Figure S7 - Supplementary Fig. S7. A. Principal component analysis (PCA), and B. Hierarchical Clustering (HCL) Analysis showing distinct difference between transcript profile of siCtrl- and siHuR-transfected A2780 cells. C and D. MA plots of gene expression of 163 genes following transfection of A2780 cells with siHuR and with siCtrl. C. 66 genes were significantly down-regulated and 50 genes were significantly up-regulated when HuR was knocked down. D. 37 significantly down-regulated genes (56%) are direct HuR targets (i.e., HuR binds to their mRNA transcript); 31 significantly up-regulated genes (62%) are direct HuR targets.
    • Supplementary Table S1 - Supplementary Table S1. Biological function of 5 up-regulated and 6 down-regulated genes having the highest fold differences in expression in response to HuR inhibition in A2780 cells. Shaded boxes indicate transcripts to which HuR binds directly.
Next
Back to top

Published OnlineFirst March 3, 2016
doi: 10.1158/0008-5472.CAN-15-2073

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Delivery of Therapeutics Targeting the mRNA-Binding Protein HuR Using 3DNA Nanocarriers Suppresses Ovarian Tumor Growth
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Delivery of Therapeutics Targeting the mRNA-Binding Protein HuR Using 3DNA Nanocarriers Suppresses Ovarian Tumor Growth
Yu-Hung Huang, Weidan Peng, Narumi Furuuchi, Jacquelyn Gerhart, Kelly Rhodes, Neelanjan Mukherjee, Masaya Jimbo, Gregory E. Gonye, Jonathan R. Brody, Robert C. Getts and Janet A. Sawicki
Cancer Res March 3 2016 DOI: 10.1158/0008-5472.CAN-15-2073

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Delivery of Therapeutics Targeting the mRNA-Binding Protein HuR Using 3DNA Nanocarriers Suppresses Ovarian Tumor Growth
Yu-Hung Huang, Weidan Peng, Narumi Furuuchi, Jacquelyn Gerhart, Kelly Rhodes, Neelanjan Mukherjee, Masaya Jimbo, Gregory E. Gonye, Jonathan R. Brody, Robert C. Getts and Janet A. Sawicki
Cancer Res March 3 2016 DOI: 10.1158/0008-5472.CAN-15-2073
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • ATR in Synovial Sarcoma
  • Cathepsin B Is Dispensable for Cathepsin B-Cleavable ADCs
  • RXRA and PPARG in Bladder Cancer
Show more Therapeutics, Targets, and Chemical Biology
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement